Bio-Techne-TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain?

Core Viewpoint - Bio-Techne Corporation's partnership with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit is expected to enhance its Diagnostics and Spatial Biology segment, despite a recent dip in stock price [1][2][3]. Company Developments - The AmplideX Nanopore Carrier Plus Kit is a new genetic panel designed for carrier screening research, providing a streamlined method for comprehensive sequencing data [1][6]. - Asuragen, a Bio-Techne brand, is recognized for high-quality molecular diagnostic products, and the partnership is anticipated to improve market sentiment towards Bio-Techne's stock [3]. - Bio-Techne has a market capitalization of $9.76 billion, with a Zacks Consensus Estimate indicating a 6.8% year-over-year increase in fiscal 2025 earnings and a 5.5% revenue improvement [4]. Product Significance - The AmplideX Nanopore Carrier Plus Kit addresses the updated ACMG recommendations for carrier screening, allowing for the analysis of genes not detectable by standard short-read sequencing [5]. - The kit includes a panel of 11 genes, such as CFTR and CYP21A2, which are prevalent but challenging to detect with traditional methods [6][7]. Industry Prospects - The global Nanopore Sequencing market is projected to grow from$ 330.59 million in 2023 to a compound annual growth rate (CAGR) of 18.07% through 2029, driven by increasing demand for DNA sequencing and technological advancements [8].